Uterine fibroids are the most common benign tumours affecting the female reproductive route though a cheap and patient-friendly treatment is still yet to be developed. They cause heavy and irregular menstrual bleeding, anaemia, pelvic pressure and pain, abortion, and in some cases death, aside their socioeconomic and psychological impact. Currently the most widely practiced methods of treatments are either surgical removal of the fibroids (myomectomy) or the uterus (hysterectomy) which do not guarantee complete recovery or cause infertility. Medicine prescribed for this poorly understood disorder only suppress the symptoms rather than treating the patient, and they cause a plethora of side effects. Though some experimental biomedical approaches and phytotherapeutic agents may become more common in the future they require intensive research before they are widely used. Interestingly, smart drug delivery utilising nanotechnological approaches has not been widely studied for this disorder though it may be the treatment patients are looking for since they can enhance bioavailability, stability and allow active agents to be effective in low doses. This article reviews the nature of uterine fibroids, methods of treatment, their major drawbacks, a few novel applications that may be beneficial for patients in the future and finally compares the nanotechnological drug delivery systems and the interprets what these studies mean for the future of the patients suffering from this disorder.